Cadrenal Therapeutics, Inc.
CVKD Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.91
KIRA · Stoqly’s AI analyst, in plain words
- Cadrenal Therapeutics, Inc. lost $13.2M in fiscal 2025.
- Free cash flow was −$12.6M in fiscal 2025, — of revenue.
Market cap
$2.7M
P/E
—
Revenue
—
Net income
−$13.2M
Free cash flow
−$12.6M
Operating margin
—
Cadrenal Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$13.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cadrenal Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Cadrenal Therapeutics, Inc.
- CIK
- 0001937993
Cadrenal Therapeutics, Inc. · CVKD
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$8.4M | −$10.7M | −$13.2M |
| Diluted EPS | −$9.29 | −$8.73 | −$6.64 |
| Cash | |||
| Cash from operations | −$3.5M | −$7.4M | −$12.6M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$3.5M | −$7.4M | −$12.6M |
| Share count change | — | 35.6% | 63.5% |
| Debt and strength | |||
| Cash and short-term investments | $8.4M | $10.0M | $4.0M |
| Shareholders' equity | $7.7M | $7.4M | $2.7M |
| Current ratio | 10.3x | 3.8x | 2.7x |
| Interest coverage | −2,180.8x | — | — |
| Returns and quality | |||
| Return on equity | −108.6% | −140.8% | −260.1% |
| Return on tangible equity | −108.6% | −143.2% | −483.3% |
| Altman Z'' | 3.9 | −7.8 | −44.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.5M
2 insiders
Of sales under plans
100%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cadrenal Therapeutics, Inc. · CVKD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.91 a share, the company is worth $2.7M.
Source: SEC EDGAR XBRL filings (CIK 0001937993). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.